Agreements reached under this partnership
Business Alliances- 1
Research into the development of stem cell culture technology for use in regenerative medicine
- 2
Drawing on the knowledge and experience of Professor Ochiya at Tokyo Medical University regarding stem cells and extracellular vesicles, the parties will jointly develop an optimized version of the “cell culture device” provided by RMDC.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Tokyo Medical University, Professor Ochiya Takahiro (落谷孝広) |
| Alliance partner's business activities | Research into molecular oncology, regenerative medicine, microRNAs and exosomes at the Tokyo Medical University Institute of Medical Science |
| Alliance partner's location | Tokyo Metropolitan Government |
| Type of alliance | Business Alliances |
| Details of the alliance | Research into the development of stem cell culture technology for use in regenerative medicine, Drawing on the knowledge and experience of Professor Ochiya at Tokyo Medical University regarding stem cells and extracellular vesicles, the parties will jointly develop an optimized version of the “cell culture device” provided by RMDC. |
| Contract Period | 1 July 2026 to 30 June 2027 |
| Contract Date | 21 July 2026 |
| Alliance start date | 1 July 2026 (the start date of the contractual research period) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to expand the existing collaboration, which has focused on culture conditions such as culture media and peptides, into the hardware field and develop a new culture device required for efficient stem cell culture.